Evaluation of the Prandial Treatment Adjustment Effect Via Continuous Glucose Monitoring on Type 2 Diabetes Mellitus (DM) Patients Uncontrolled With a Basal Insulin or Premix Once a Day

Inclusion criteria: Run-in period: 1. Type 2 diabetes 2. HbA1c≥ 8.5% (in a test of the last month) 3. Age above 21 years 4. Patients continuously treated with basal insulin or mixed insulin once daily for the last 6 months 5. Signed informed consent form 6. Patients who according to their physician are eligible to the study Randomization: 1. HbA1c \> 7.5% 2. FPG \< 130 mg/dl Exclusion criteria: 1. Type 1 diabetes 2. Patients continuously treated with short-acting insulin or mixed insulin more than once daily for 3 weeks during the last 6 months. 3. Pregnant or breastfeeding women. 4. Patients with allergy to insulin. 5. Patients with severe diseases characterized by recurrent hospitalizations, including: Severe renal insufficiency, severe cardiac insufficiency, active oncological disease or oncological disease requiring chemotherapy. 6. Patients with mobility difficulties and/or difficulties communicating with the investigator The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.